Abstract
Objective To investigate the expression of kinesin family member 20A (KIF20A) in bladder cancer, the effect of KIF20A on the proliferation and metastasis of bladder cancer cells, and the effect of KIF20A expression on the prognosis of bladder cancer patients. Methods Bladder cancer tissue and its adjacent tissues were collected from tumour patients. The mRNA and protein expression levels of KIF20A in the tissue samples were detected by qRT-PCR and western blot. Immunohistochemical (IHC) staining was used to identify the expression and distribution of KIF20A proteins in the tissue samples. The relationship between the KIF20A expression and the clinical pathology of bladder cancer was analysed. The effect of the differential expression of KIF20A on the prognosis of patients with bladder cancer was analysed by the TCGA database. The plasmid was transfected into the bladder cell lines T24 and 5637 to construct two stable cell lines with knocked down KIF20A. The effect of KIF20A expression on the proliferation and invasion of T24 and 5637 bladder cells was explored in vitro using the abovementioned stable cell lines. The effect of the KIF20A expression on the proliferation of bladder cancer cells was evaluated by a mouse xenograft model. Results The expression of KIF20A was significantly higher in the bladder cancer tissues than in the adjacent control tissues. The expression of KIF20A was significantly associated with the degree of pathological differentiation of bladder cancer. Patients with a higher expression of KIF20A had a higher tumour grade and a more advanced stage. The mean survival of patients with a high KIF20A expression was significantly lower than the mean survival of patients with a low KIF20A expression. The in vitro experiments demonstrated that the knockdown of KIF20A significantly inhibited T24 and 5637 cell proliferation and invasion. The in vivo experiments showed that the knockdown of KIF20A significantly inhibited the proliferation of the bladder tumours. Conclusion KIF20A promotes the proliferation and metastasis of bladder cancer cells. Bladder cancer patients with a high KIF20A expression have a worse tumour differentiation and a poor prognosis. KIF20A may become an independent factor that affects the prognosis of bladder cancer patients and a therapeutic target for bladder cancer.
Highlights
Bladder cancer is one of the most common malignant tumours in the urinary system
We first used qRT-PCR to detect the mRNA expression level of Kinesin family member 20A (KIF20A) in the above samples (Figure 1(a)) and found that the mRNA expression level of KIF20A was higher in the bladder cancer tissues than in the adjacent tissues of 16 sample pairs
The results showed that the protein levels of KIF20A in the bladder cancer cell lines were higher than those in the normal bladder cell line (Figure 3(a))
Summary
Bladder cancer is one of the most common malignant tumours in the urinary system. The estimated number of new bladder cancer cases increased from 79030 in 2017 to 81190 in 2018 in the United States. The number of deaths increased from 16870 to 17240 [1, 2]. Treating bladder cancer is often difficult and expensive [3]. Bladder cancer morbidity and mortality have increased in the Chinese population. Current chemotherapy methods and surgery can effectively prolong the survival of patients with bladder cancer, and patients need to bear the high expenses and pain caused by surgical treatment. Finding molecular markers that are potential therapeutic targets and prognostic indicators of bladder cancer is critical for a clinically accurate diagnosis and treatment
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
